UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults ...

The Bills exit their bye at 5-1 with Maxwell Hairston struggling outside and Greg Rousseau rushing alone, and Zay Flowers and ...

Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy across multiple solid tumor types. As of the August 7, 2026 data cutoff, 98 heavily pretreated patients across ...

In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.

Zai Lab reported an 81.8% response rate for zoci plus atezolizumab in a Phase 1b small cell lung cancer trial and plans a ...

Baker Mayfield wants reads, footwork and ball security cleaned up as he returns to lead the NFL's 30th-ranked passing offense into Carolina on Sunday.

Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic ...

OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC ...

Virginia Tech comes to Clemson with a profile that makes this matchup difficult to read. The Hokies have clear strengths, some meaningful vulnerabilities, and enough balance to make this one more than ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from ...

Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027. Investor webcast foc ...

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support ...